MedTrace Logo

Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis

NCT01985464 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-06-20

No results posted yet for this study

Summary

Allogeneic human umbilical cord tissue-derived stem cells will be injected intravenously once per day for 5 days is a safe and useful procedure in inducing remission of RA in patients resistant to standard DMARD therapy.

Conditions

Interventions

BIOLOGICAL

Umbilical cord mesenchymal stem cells

Sponsors & Collaborators

  • Translational Biosciences

    lead INDUSTRY

Principal Investigators

  • Gerardo Castrellon, MD · Not Affiliated

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2019-12-31
Completion
2020-06-30

Countries

  • Panama

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01985464 on ClinicalTrials.gov